These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30347787)

  • 1. Metallothionein and Superoxide Dismutase-Antioxidative Protein Status in Fullerene-Doxorubicin Delivery to MCF-7 Human Breast Cancer Cells.
    Kepinska M; Kizek R; Milnerowicz H
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Fullerenes as Doxorubicin Nano-Transporters on Metallothionein and Superoxide Dismutase Status in MCF-10A Cells.
    Zaręba N; Więcławik K; Kizek R; Hosnedlova B; Kepinska M
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35056998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C60 fullerene as synergistic agent in tumor-inhibitory Doxorubicin treatment.
    Prylutska S; Grynyuk I; Matyshevska O; Prylutskyy Y; Evstigneev M; Scharff P; Ritter U
    Drugs R D; 2014 Dec; 14(4):333-40. PubMed ID: 25504158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of C60 Fullerene-Doxorubicin Complex for Tumor Cell Treatment In Vitro and In Vivo.
    Panchuk RR; Prylutska SV; Chumakl VV; Skorokhyd NR; Lehka LV; Evstigneev MP; Prylutskyy YI; Berger W; Heffeter P; Scharff P; Ritter U; Stoika RS
    J Biomed Nanotechnol; 2015 Jul; 11(7):1139-52. PubMed ID: 26307837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of anticancer activity in cells of novel stoichiometric pegylated fullerene-doxorubicin conjugates.
    Magoulas GE; Bantzi M; Messari D; Voulgari E; Gialeli C; Barbouri D; Giannis A; Karamanos NK; Papaioannou D; Avgoustakis K
    Pharm Res; 2015 May; 32(5):1676-93. PubMed ID: 25380982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fullerene as a doxorubicin nanotransporter for targeted breast cancer therapy: Capillary electrophoresis analysis.
    Kepinska M; Kizek R; Milnerowicz H
    Electrophoresis; 2018 Sep; 39(18):2370-2379. PubMed ID: 29931716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C
    Hurmach Y; Rudyk M; Prylutska S; Hurmach V; Prylutskyy YI; Ritter U; Scharff P; Skivka L
    Mol Pharm; 2020 Sep; 17(9):3622-3632. PubMed ID: 32673486
    [No Abstract]   [Full Text] [Related]  

  • 8. C60 fullerene prevents genotoxic effects of doxorubicin in human lymphocytes in vitro.
    Afanasieva KS; Prylutska SV; Lozovik AV; Bogutska KI; Sivolob AV; Prylutskyy YI; Ritter U; Scharff P
    Ukr Biochem J; 2015; 87(1):91-8. PubMed ID: 26036135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tumoral acidic pH-responsive drug delivery system based on a novel photosensitizer (fullerene) for in vitro and in vivo chemo-photodynamic therapy.
    Shi J; Liu Y; Wang L; Gao J; Zhang J; Yu X; Ma R; Liu R; Zhang Z
    Acta Biomater; 2014 Mar; 10(3):1280-91. PubMed ID: 24211343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newly Synthesized Doxorubicin Complexes with Selected Metals-Synthesis, Structure and Anti-Breast Cancer Activity.
    Jabłońska-Trypuć A; Świderski G; Krętowski R; Lewandowski W
    Molecules; 2017 Jul; 22(7):. PubMed ID: 28677642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fullerene (C60)-based tumor-targeting nanoparticles with "off-on" state for enhanced treatment of cancer.
    Shi J; Wang B; Wang L; Lu T; Fu Y; Zhang H; Zhang Z
    J Control Release; 2016 Aug; 235():245-258. PubMed ID: 27276066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells.
    Akman SA; Forrest G; Chu FF; Esworthy RS; Doroshow JH
    Cancer Res; 1990 Mar; 50(5):1397-402. PubMed ID: 2406012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of C60 fullerene complexed to doxorubicin with model bilipid membranes and its uptake by HeLa cells.
    Prylutskyy Y; Bychko A; Sokolova V; Prylutska S; Evstigneev M; Rybalchenko V; Epple M; Scharff P
    Mater Sci Eng C Mater Biol Appl; 2016 Feb; 59():398-403. PubMed ID: 26652389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
    Sun B; Deng C; Meng F; Zhang J; Zhong Z
    Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
    Shaik MS; Chatterjee A; Singh M
    J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotection against doxorubicin by metallothionein Is associated with preservation of mitochondrial biogenesis involving PGC-1α pathway.
    Guo J; Guo Q; Fang H; Lei L; Zhang T; Zhao J; Peng S
    Eur J Pharmacol; 2014 Aug; 737():117-24. PubMed ID: 24858368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metallothionein prevents doxorubicin cardiac toxicity by indirectly regulating the uncoupling proteins 2.
    Jing L; Yang M; Li Y; Yu Y; Liang B; Cao L; Zhou X; Peng S; Sun Z
    Food Chem Toxicol; 2017 Dec; 110():204-213. PubMed ID: 29061315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells.
    Du GJ; Song ZH; Lin HH; Han XF; Zhang S; Yang YM
    Biochem Biophys Res Commun; 2008 Aug; 372(3):497-502. PubMed ID: 18503759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic Fullerene-DNA/Hyaluronic Acid Nanovehicles with Magnetism/Reduction Dual-Responsive Triggered Release.
    Wang L; Wang Y; Hao J; Dong S
    Biomacromolecules; 2017 Mar; 18(3):1029-1038. PubMed ID: 28221040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QbD-based development of α-linolenic acid potentiated nanoemulsion for targeted delivery of doxorubicin in DMBA-induced mammary gland carcinoma: in vitro and in vivo evaluation.
    Tripathi CB; Parashar P; Arya M; Singh M; Kanoujia J; Kaithwas G; Saraf SA
    Drug Deliv Transl Res; 2018 Oct; 8(5):1313-1334. PubMed ID: 29748834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.